KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Q4 2025 value amounting to $965.3 million.

  • Alnylam Pharmaceuticals' Operating Expenses rose 3823.29% to $965.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $3.2 billion, marking a year-over-year increase of 3246.14%. This contributed to the annual value of $3.2 billion for FY2025, which is 3246.14% up from last year.
  • According to the latest figures from Q4 2025, Alnylam Pharmaceuticals' Operating Expenses is $965.3 million, which was up 3823.29% from $881.0 million recorded in Q3 2025.
  • Over the past 5 years, Alnylam Pharmaceuticals' Operating Expenses peaked at $965.3 million during Q4 2025, and registered a low of $360.0 million during Q1 2022.
  • For the 5-year period, Alnylam Pharmaceuticals' Operating Expenses averaged around $556.2 million, with its median value being $537.2 million (2023).
  • Per our database at Business Quant, Alnylam Pharmaceuticals' Operating Expenses crashed by 105.24% in 2022 and then surged by 5247.62% in 2025.
  • Quarter analysis of 5 years shows Alnylam Pharmaceuticals' Operating Expenses stood at $453.1 million in 2021, then grew by 15.57% to $523.6 million in 2022, then grew by 6.2% to $556.1 million in 2023, then grew by 25.57% to $698.3 million in 2024, then soared by 38.23% to $965.3 million in 2025.
  • Its Operating Expenses stands at $965.3 million for Q4 2025, versus $881.0 million for Q3 2025 and $789.9 million for Q2 2025.